Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Metabolite Profiling of [14C]-A4250 in Healthy Males
NCT03082937Phase 1Completed
- Sponsor
- Albireo Pharma
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and primary biliary cholangitis (PBC), sponsored by Albireo Pharma. Primary endpoints: Mass balance recovery of total radioactivity in urine, Mass balance recovery of total radioactivity in faeces and 3 more. Started Jan 2017; status: completed.
02
Drugs
odevixibat
03
Conditions
progressive familial intrahepatic cholestasis (PFIC)Alagille syndrome (ALGS)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03082937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082937.